The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.

NEW YORK – Digital pathology company OptraScan announced on Tuesday that it has closed a $30 million Series B financing round. The round was led by molecular diagnostics firm Molbio Diagnostics. The ...

NEW YORK — UK-based iFast Diagnostics said on Tuesday that it has raised $6.5 million in seed funding. The financing round was led by KHP Ventures and included EInk, Raw Ventures, and OKG Capital, as ...

Fadel Alshalabi, owner and CEO of Crestar Labs, and Samuel Harris, owner of Flojo Recruiting conspired to bill Medicare and Medicaid for millions of dollars in genetic test orders.

The firm reported a 13 percent jump in its non-COVID molecular diagnostics revenues year over year while its breast health and GYN Surgical business revenues rose 6 percent.

Last week, readers were most interested in a story about the FDA's clearance of Qiagen's QiaStat-Dx Respiratory Panel Mini syndromic multiplex qPCR test.

The firm said that demand has increased for its 10-minute sepsis risk test as it can save lives, reduce hospital stays, and reduce healthcare costs.

The firm also appointed Aaron Roebuck as president, saying he will help the company to develop and commercialize its breath-based testing platform.

The researchers used publicly available data from companies such as Guardant Health, Exact Sciences, and Geneoscopy to determine possible effects of blood-based tests.

Out of the 30 companies tracked by 360Dx, 22 saw their share prices decline, seven saw their stock prices increase, and one company’s shares remained essentially flat.

The parliamentary resolution drew the immediate support of MedTech Europe and VDGH, but it remains unclear what the immediate ...

Daniel Canchola defrauded Medicare by prescribing unnecessary durable medical equipment and cancer genetic testing in exchange for kickbacks.